Stay updated on CT103A in Relapsed/Refractory Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the CT103A in Relapsed/Refractory Multiple Myeloma Clinical Trial page.

Latest updates to the CT103A in Relapsed/Refractory Multiple Myeloma Clinical Trial page
- Check4 days agoChange DetectedRecord History shows a new revision (v3.3.4) with sponsor Nanjing IASO Biotechnology Co., Ltd., and status notes such as 'Last known status was: Unknown status' and 'Verified'; the previous revision v3.3.3 appears to have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedA new revision entry Revision: v3.3.3 was added to the record history, and the HHS Vulnerability Disclosure and Revision: v3.3.2 were removed from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check55 days agoChange DetectedThe Record History now shows a new revision entry v3.3.2 and removes the previous v3.3.1 entry.SummaryDifference0.1%

- Check62 days agoChange DetectedThe page history now shows Revision: v3.3.1 added and Revision: v3.2.0 removed; no changes to study data or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check69 days agoChange DetectedThe government funding notice banner at the top of the page was removed.SummaryDifference0.9%

- Check83 days agoChange DetectedVersion history shows no substantive changes to the study record; the 2023-01-13 entry lists 'Changes: None'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to CT103A in Relapsed/Refractory Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CT103A in Relapsed/Refractory Multiple Myeloma Clinical Trial page.